Zevra Therapeutics reports positive pediatric data
- Zevra Therapeutics (NASDAQ:ZVRA) reported positive phase 2/3 pediatric substudy data for arimoclomol in infants with Niemann-Pick disease type C.
- The 5-patient study showed the therapy was generally well tolerated with no new safety signals identified.
- Pharmacokinetics were consistent with older pediatric groups when used alongside miglustat.
Zevra Therapeutics (NASDAQ:ZVRA) reported positive data for MIPLYFFA (arimoclomol) from a phase 2/3 open-label pediatric substudy in infants with Niemann-Pick disease type C.
The study evaluated five patients aged between 12 and under 24 months and assessed the therapy when added to miglustat as part of combination treatment.
No executive quote was included in the reported study summary, so the results are presented as clinical trial findings without attributed commentary.
The company said arimoclomol was generally well tolerated and reported no new safety signals, while pharmacokinetic results were consistent with data from older pediatric groups.
Zevra Therapeutics develops therapies for rare neurological and metabolic conditions, with MIPLYFFA positioned as part of its pipeline targeting Niemann-Pick disease type C.
The study adds to earlier clinical evidence supporting arimoclomol use in pediatric populations, particularly when combined with existing therapy such as miglustat.
